Drug

Sabatolimab

In clinical development

ClassHepatitis A virus cellular receptor 2 inhibitorEmerging researchLate-stage development

RxNorm2631079 ChEMBLCHEMBL4594575 ATCL01FX19UNII3L7R886Y06

Research papers

Active clinical trials

HAVCR2

Primary target

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

An Open-label, Multicenter, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Clinical trial2026-01-07Results expected Q1 2028 · ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

Clinical trial2024-10-02Terminated · ClinicalTrials.gov

A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Myelofibrosis Patients

Clinical trial2024-08-28Terminated · ClinicalTrials.gov

A Phase Ib/II, Open Label Study of Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation

Clinical trial2024-08-22Terminated · ClinicalTrials.gov

A Single-arm, Open-label, Phase II Study of Sabatolimab in Combination With Azacitidine and Venetoclax in Adult Participants With High or Very High Risk Myelodysplastic Syndromes (MDS) as Per IPSS-R Criteria

Clinical trial2023-05-08Terminated · ClinicalTrials.gov

Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors.

Research2021-04-21Clinical cancer research : an official journal of the American Association for Cancer Research

A Phase Ib/II, Open Label, Proof-of-concept Study of Sabatolimab and Magrolimab-based Therapy for Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Clinical trial2029-10-26Withdrawn · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Sabatolimab

RxNorm CUI

2631079

ChEMBL ID

CHEMBL4594575

ATC codes

L01FX19

UNII

3L7R886Y06

Primary mechanism

Hepatitis A virus cellular receptor 2 inhibitor

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Hepatitis A virus cellular receptor 2

HAVCR2 · Q8TDQ0

INHIBITORHepatitis A virus cellular receptor 2 inhibitor

Clinical trials

6 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

Active studies

Late-stage (III+)

Discontinued

PHASE DISTRIBUTIONn = 6

Phase 1 / 23Phase 22Phase 31

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

TerminatedPH IIINovartis Pharmaceuticalsn=5302024

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research · 2021 · 285 cites

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Spartalizumab

Studied across the same disease area as Sabatolimab in the shared literature.

1 shared disease1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials